Condition (MeSH)
Neoplasm Regression, Spontaneous
ClinicalTrials.gov lists 2 trials for Neoplasm Regression, Spontaneous or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
2 of the 2 trials are tagged with Neoplasm Regression, Spontaneous itself; the rest are tagged with a narrower condition beneath it.
When did Neoplasm Regression, Spontaneous trials start? (2)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2019 | 1 |
| 2015 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 2 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Neoplasm Regression, Spontaneous trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Not applicable | 1 |
| Observational | 1 |
How many Neoplasm Regression, Spontaneous trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which publications cover Neoplasm Regression, Spontaneous? (31)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Outcome of expectant management of cervical intraepithelial neoplasia grade 2 in women followed for 12 months. | European journal of obstetrics, gynecology, and reproductive biology | 2011 | Yes |
| Local immune response in the microenvironment of CIN2-3 with and without spontaneous regression. | Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc | 2010 | Yes |
| Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2009 | Yes |
| Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. | Obstetrics and gynecology | 2009 | Yes |
| Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2008 | Yes |
Showing 5 of 31 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.